Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

BACKGROUND: Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-naïve and pre-treated MS patients who had been prescribed GA for 1 year, to investigate reasons for GA prescription, its effectiveness and safety in re...

Descripción completa

Detalles Bibliográficos
Autores principales: Zecca, Chiara, Disanto, Giulio, Sacco, Rosaria, Riccitelli, Gianna C., Gobbi, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626416/
https://www.ncbi.nlm.nih.gov/pubmed/31299922
http://dx.doi.org/10.1186/s12883-019-1383-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626416/
https://www.ncbi.nlm.nih.gov/pubmed/31299922
http://dx.doi.org/10.1186/s12883-019-1383-6

Ejemplares similares